Ragusa Antonio, Ficarola Fernando, Ferrari Amerigo, Spirito Nicoletta, Ardovino Mario, Giraldi Domenico, Stuzziero Elisario, Rinaldo Denise, Procaccianti Roberto, Larciprete Giovanni, De Luca Caterina, D'Avino Sara, Principi Giulia, Angioli Roberto, Svelato Alessandro
Department of Obstetrics and Gynecology, Maggiore Hospital Carlo Alberto Pizzardi Bologna, Italy.
Unit of Gynecology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
EClinicalMedicine. 2024 May 31;73:102665. doi: 10.1016/j.eclinm.2024.102665. eCollection 2024 Jul.
To assess the equivalence of tranexamic acid (TRAN) versus synthetic oxytocin (OXY) in reducing post-partum blood loss, in full-term patients (37-42 weeks), at low risk of post-partum hemorrhage, with vaginal childbirth.
Phase III, randomized (1:1), open-label, longitudinal, multi-center, prospective clinical trial (Prot. n 63209, ClinicalTrials.gov Identifier: NCT02775773). From January 7, 2020, to June 30, 2023, a total of 256 women were enrolled at two general urban community hospitals in Italy, serving a multi-ethnic patient population with National Health Insurance. The primary outcome was to explore a potential equivalence between the two treatments (OXY and TRAN) in preventing total blood loss. Therefore, we randomized 231 women into two groups: Group A (OXY), 127 women who were administered 10UI intramuscularly within 5 min from childbirth; Group B (TRAN), 104 women to whom 1-g slow intravenous infusion was administered within 5 min from childbirth.
At the time of delivery, mean blood loss for OXY group versus TRAN group was 269.12 mL versus 263.88 mL, respectively, with equivalence between the two groups. Similarly, there was equivalence in total blood loss between the OXY and the TRAN group (397.66 mL versus 405.64 mL, respectively. No statistical differences between Hb levels at admission and discharge in the two groups were reported. No difference was found in terms of additional uterotonic and surgical therapies between the two groups of patients. Neither group showed thrombotic complications at check-up performed after 7 days or after a questionnaire regarding adverse effects, subjected after 40 days.
The study shows the equivalence of tranexamic acid versus synthetic oxytocin in post-partum blood loss prophylaxis in term patients at low risk of PPH with vaginal childbirth. The safety profiles of OXY and TRAN were similar.
None.
评估氨甲环酸(TRAN)与合成缩宫素(OXY)在足月(37 - 42周)、产后出血低风险且经阴道分娩的患者中减少产后失血的等效性。
III期、随机(1:1)、开放标签、纵向、多中心、前瞻性临床试验(方案编号63209,ClinicalTrials.gov标识符:NCT02775773)。从2020年1月7日至2023年6月30日,意大利两家城市综合社区医院共招募了256名妇女,这些医院服务于具有国家医疗保险的多民族患者群体。主要结局是探讨两种治疗方法(OXY和TRAN)在预防总失血量方面的潜在等效性。因此,我们将231名妇女随机分为两组:A组(OXY),127名妇女在分娩后5分钟内接受10单位肌肉注射;B组(TRAN),104名妇女在分娩后5分钟内接受1克缓慢静脉输注。
分娩时,OXY组与TRAN组的平均失血量分别为269.12毫升和263.88毫升,两组之间具有等效性。同样,OXY组和TRAN组的总失血量也具有等效性(分别为397.66毫升和405.64毫升)。两组入院时和出院时的血红蛋白水平无统计学差异。两组患者在额外使用宫缩剂和手术治疗方面没有差异。在7天后的检查或40天后关于不良反应的问卷调查中,两组均未出现血栓形成并发症。
该研究表明,在产后出血低风险的足月经阴道分娩患者中,氨甲环酸与合成缩宫素在预防产后失血方面具有等效性。OXY和TRAN的安全性相似。
无。